MMP-2 -1575G/A polymorphism modifies the onset of optic neuritis as a first presenting symptom in MS?

J Neuroimmunol. 2015 Sep 15:286:13-5. doi: 10.1016/j.jneuroim.2015.06.014. Epub 2015 Jul 2.

Abstract

Previous studies show altered activities of matrix metalloproteinase (MMP)-2 and MMP-9 in serum and cerebrospinal fluid of multiple sclerosis (MS) and neuromyelitis optica (NMO) patients. Optic neuritis (ON) is a common symptom of both disorders. Here we investigated the impacts of MMP-2 -1575G/A and MMP-9 -1562 C/T gene polymorphisms on disease phenotype in 100 MS patients with ON as a first symptom and 376 MS patients with other initial symptomatology. The MMP-2 -1575G/A polymorphism led to a 5-year-earlier age of disease onset in MS patients with ON as a first symptom (p=0.009).

Keywords: Age of disease onset; MMP-2; MMP-9; Multiple sclerosis; Optic neuritis; Susceptibility.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age of Onset
  • Analysis of Variance
  • Animals
  • Disability Evaluation
  • Gene Frequency
  • Genetic Association Studies
  • Genotype
  • Humans
  • Male
  • Matrix Metalloproteinase 2 / genetics*
  • Matrix Metalloproteinase 9 / genetics
  • Multiple Sclerosis / complications*
  • Multiple Sclerosis / genetics*
  • Optic Neuritis / complications*
  • Optic Neuritis / genetics*
  • Polymorphism, Single Nucleotide / genetics*
  • Rats, Sprague-Dawley
  • Young Adult

Substances

  • Matrix Metalloproteinase 2
  • Matrix Metalloproteinase 9